By continuing to use our. Stockhouse. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. THTX | Complete Theratechnologies Inc. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. M. This news release constitutes a “designated news release” for the purposes of the. com uses cookies on this site. MONTREAL, Jan. TH | May 19, 2023. 08). Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. lgibson. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. . sBLA for F8 formulation of tesamorelin submitted to FDA. By continuing to use our service, you agree to our use of cookies. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. 5% workforce reduction. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. TO) on CEO. 75%. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. THTX earnings call for the period ending February 29, 2020. By continuing to use our service, you agree to our use of cookies. The Theratechnologies Inc. RESSOURCES. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TH. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. m. 514-336-7800. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Stockhouse. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. Contact Email communications@theratech. Losses were -47. Theratechnologies. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). Theratechnologies Inc. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. We also use them to share usage. (882) posted 3 minutes ago. 4 million. 9 million as at August 31, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Patient assistance: 833-238-4372. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. com uses cookies on this site. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Microsoft to invest $500M in Quebec AI economy. ET. Montréal, Québec, Canada . About Us | Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (THTX) NasdaqCM - NasdaqCM Real Time Price. T. We also use them to share usage information with our partners. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. Consensus forecasts updated Jul 21. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. com. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Investor inquiries: Elif McDonald. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . Cookies are used to offer you a better browsing experience and to analyze our traffic. T. MONTREAL, Oct. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Phone Number (514) 336-7800. com uses cookies on this site. We also use them to share usage information with our partners. 51 S1. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. com. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. NCU. FAQ – Utilisateurs de TMX Argent NOUVEAU. 72%. - Issued and outstanding common shares to be consolidated on the basis of 1 post. Cookies are used to offer you a better browsing experience and to analyze our traffic. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. is a speaker and consultant of Theratechnologies. Company Participants. Follow. S. stock news by MarketWatch. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. By continuing to use our service, you agree to our use of cookies. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. 1-438. Find the latest Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. About Theratechnologies. (TH. Theratechnologies last announced its earnings data on September 26th, 2023. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. MONTREAL, Sept. By continuing to use our service, you agree to our use of cookies. The price has fallen in 5 of the last 10 days. stock price gained 1. 23 to a day high of $1. View analysts price targets for THTX. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. $30. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Further. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies (THTX) Stock Price, News & Analysis $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. It is the Company’s proprietary peptide linked to. 67% from the latest price. We also use them to share usage information with our partners. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. FY2022 revenue. MONTREAL, Oct. TH | Complete Theratechnologies Inc. Investor Relations. T. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. MONTREAL, Dec. MONTREAL, Nov. Non-Profit & Charitable Organizations · United States · <25 Employees. Trogarzo® and. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. 2% for this period. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Q3 2022 Consolidated Revenue Growth of 17% to $20. D. Find the latest Theratechnologies Inc. Theratechnologies Announces 1-for-4 Reverse Stock Split. S. Company Type For Profit. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). $109. Theratechnologies inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. communications@theratech. Stockhouse. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. - October 10, 2023) - KO Gold Inc. The abstract and poster can be found on Theratechnologies’ website. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Stockhouse. W. . (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. stock news by MarketWatch. Theratechnologies layoffs. 05M. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Heures de négociation. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. TH | October 13, 2022 - Q3 2022 Consolidated. MONTREAL, Oct. By continuing to use our service, you agree to our use of cookies. 89 52. com uses cookies on this site. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. TH | September 26, 2023. 86%. $30. Stockhouse. Betteryear2. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. 25. Theratechnologies inc. . Montréal, Québec, Canada . Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. 617-356-1009. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 00. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Paul Levesque - President. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Oct. Theratechnologies is pepped up on peptides. Stockhouse. 23) diluted earnings per. Denis Boucher. 25 to $1. 1M. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. 72%. TH1902 combines Theratechnologies’ proprietary peptide to. Track Theratechnologies Inc. 82 million. " The 12-month stock price forecast is $18. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 00 to $36. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . com. MONTREAL, Aug. We also use them to share usage. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Pour les émetteurs. TORONTO, Sept. com uses cookies on this site. Shares of Theratechnologies are up 4. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Real-time discussion about Theratechnologies Inc. com. 39 50-Day Range $0. Saint-Laurent, Canada. We also use them to share usage. stock news by MarketWatch. Theratechnologies Inc. Stockhouse. Apr 14, 2020, 8:30 a. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. com. 51 to 200 Employees. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. 8. - 2023 Q3 positive adjusted EBITDA to be. ET. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. 2% to $21. MONTREAL, Nov. Theratechnologies develops and commercializes innovative therapies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. 31K. MONTREAL, Sept. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. THERATECHNOLOGIES INC. The reported ($0. Cookies are used to offer you a better browsing experience and to analyze our traffic. Gary Littlejohn Stockhouse. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. 22M. com uses cookies on this site. MONTREAL, Feb. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. VANCOUVER, British Columbia, Nov. com uses cookies on this site. com uses cookies on this site. 0. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. However, only about 4% of the stocks on the OTC market fall into this category. 71%. was a. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. About TH1902. L. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. T. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. 8 and 1. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. The webinar will also address system-level barriers and present real-world. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. The abstracts are now available at aacr. com. Theratechnologies Inc. We also use them to. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. View recently published Stock News reports from independent reports and journalists. Revenues have been growing at an average rate of 10. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. 4% from the stock's current price. Herein, we report. Message Board Total Posts: 4. 03) EPS for the quarter, beating the consensus estimate of ($0. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Vice President, Communications and Corporate Affairs. Stockhouse. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. 10% most volatile stocks in CA Market. com uses cookies on this site. Theratechnologies's earnings have been declining at an average annual rate of -35. . 35 as of 10:41 a. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. (“Theratechnologies”) with the Securities and Exchange Commission (the. View real-time stock prices and stock quotes for a full financial overview. By continuing to use our service, you agree to our use of cookies. 89 $2. 2. Register for your free account today at data. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Image source: The Motley Fool. com uses cookies on this site. Senior Director, Investor Relations. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. These pharmaceuticals. licensed the product from TaiMed Biologics, Inc. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Marsolais will present at the H. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. MONTREAL, Feb. US Headquarters. Theratechnologies Inc. - TH1902 Phase 1 basket trial proceeding as planned. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Cookies are used to offer you a better browsing experience and to analyze our traffic. View real-time stock prices and stock quotes for a full financial overview. communications@theratech. Learn why it. ( THTX 3. 06 million, an increase of 14. One reason for that is that this tier does not include penny stocks. Stockhouse. Gary Littlejohn. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. GUD | Complete Knight Therapeutics Inc. 63. THERATECHNOLOGIES INC. Cookies are used to offer you a better browsing experience and to analyze our traffic. For investor inquiries: Leah Gibson. Theratechnologies Inc. TH | July 20, 2023. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.